337. Row D., Weiser M. R. Anorectal melanoma // Clinics in colon and rectal surgery. ‒ 2009. ‒ T. 22, № 2. ‒ C. 120.
338. Matsuda A., Miyashita M., Matsumoto S., Takahashi G., Matsutani T., Yamada T., Kishi T., Uchida E. Abdominoperineal resection provides better local control but equivalent overall survival to local excision of anorectal malignant melanoma: a systematic review // Annals of surgery. ‒ 2015. ‒ T. 261, № 4. ‒ C. 670-677.
339. Diller M. L., Martin B. M., Delman K. A. Lymph node dissection for stage III melanoma // Surg Oncol Clin N Am. ‒ 2015. ‒ T. 24, № 2. ‒ C. 261-77.
340. Mozzillo N., Caraco C., Marone U., Di Monta G., Crispo A., Botti G., Montella M., Ascierto P. A. Superficial and deep lymph node dissection for stage III cutaneous melanoma: clinical outcome and prognostic factors // World J Surg Oncol. ‒ 2013. ‒ T. 11. ‒ C. 36.
341. Galliot-Repkat C., Cailliod R., Trost O., Danino A., Collet E., Lambert D., Vabres P., Dalac S. The prognostic impact of the extent of lymph node dissection in patients with stage III melanoma // Eur J Surg Oncol. ‒ 2006. ‒ T. 32, № 7. ‒ C. 790-4.
342. Hughes T. M., Thomas J. M. Combined inguinal and pelvic lymph node dissection for stage III melanoma // Br J Surg. ‒ 1999. ‒ T. 86, № 12. ‒ C. 1493-8.
343. Shen P., Conforti A. M., Essner R., Cochran A. J., Turner R. R., Morton D. L. Is the node of Cloquet the sentinel node for the iliac/obturator node group? // Cancer J. ‒ 2000. ‒ T. 6, № 2. ‒ C. 93-7.
344. Balch C. M., Gershenwald J. E., Soong S. J., Thompson J. F., Atkins M. B., Byrd D. R., Buzaid A. C., Cochran A. J., Coit D. G., Ding S., Eggermont A. M., Flaherty K. T., Gimotty P. A., Kirkwood J. M., McMasters K. M., Mihm M. C., Jr., Morton D. L., Ross M. I., Sober A. J., Sondak V. K. Final version of 2009 AJCC melanoma staging and classification // J Clin Oncol. ‒ 2009. ‒ T. 27, № 36. ‒ C. 6199-206.
345. Kirkwood J. M., Manola J., Ibrahim J., Sondak V., Ernstoff M. S., Rao U. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma // Clin Cancer Res. ‒ 2004. ‒ T. 10, № 5. ‒ C. 1670-7.
346. Petrella T. Systemic Adjuvant Therapy for Patients at High Risk for Recurrent Melanoma: Updated Guideline Recommendations 2009 // Book Systemic Adjuvant Therapy for Patients at High Risk for Recurrent Melanoma: Updated Guideline Recommendations 2009 / Editor, 2009.
347. Kirkwood J. M., Ibrahim J. G., Sondak V. K., Richards J., Flaherty L. E., Ernstoff M. S., Smith T. J., Rao U., Steele M., Blum R. H. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190 // J Clin Oncol. ‒ 2000. ‒ T. 18, № 12. ‒ C. 2444-58.
348. Kirkwood J. M., Ibrahim J. G., Sosman J. A., Sondak V. K., Agarwala S. S., Ernstoff M. S., Rao U. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801 // J Clin Oncol. ‒ 2001. ‒ T. 19, № 9. ‒ C. 2370-80.
349. Kirkwood J. M., Strawderman M. H., Ernstoff M. S., Smith T. J., Borden E. C., Blum R. H. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684 // J Clin Oncol. ‒ 1996. ‒ T. 14, № 1. ‒ C. 7-17.
350. Wheatley K., Ives N., Eggermont A., Kirkwood J., Cascinelli N., Markovic S. N., Hancock B., Lee S., Suciu S., on behalf of International Malignant Melanoma Collaborative Group. Interferon-{alpha} as adjuvant therapy for melanoma: An individual patient data meta-analysis of randomised trials // ASCO Meeting Abstracts. ‒ 2007. ‒ T. 25, № 18_suppl. ‒ C. 8526.
351. Eggermont A. M. M., Blank C. U., Mandala M., Long G. V., Atkinson V., Dalle S., Haydon A., Lichinitser M., Khattak A., Carlino M. S., Sandhu S., Larkin J., Puig S., Ascierto P. A., Rutkowski P., Schadendorf D., Koornstra R., Hernandez-Aya L., Maio M., van den Eertwegh A. J. M., Grob J. J., Gutzmer R., Jamal R., Lorigan P., Ibrahim N., Marreaud S., van Akkooi A. C. J., Suciu S., Robert C. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma // N Engl J Med. ‒ 2018. ‒ T. 378, № 19. ‒ C. 1789-1801.
352. Weber J., Mandala M., Del Vecchio M., Gogas H. J., Arance A. M., Cowey C. L., Dalle S., Schenker M., Chiarion-Sileni V., Marquez-Rodas I., Grob J. J., Butler M. O., Middleton M. R., Maio M., Atkinson V., Queirolo P., Gonzalez R., Kudchadkar R. R., Smylie M., Meyer N., Mortier L., Atkins M. B., Long G. V., Bhatia S., Lebbe C., Rutkowski P., Yokota K., Yamazaki N., Kim T. M., de Pril V., Sabater J., Qureshi A., Larkin J., Ascierto P. A., CheckMate C. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma // N Engl J Med. ‒ 2017. ‒ T. 377, № 19. ‒ C. 1824-1835.
353. Burmeister B. H., Henderson M. A., Ainslie J., Fisher R., Di Iulio J., Smithers B. M., Hong A., Shannon K., Scolyer R. A., Carruthers S., Coventry B. J., Babington S., Duprat J., Hoekstra H. J., Thompson J. F. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial // Lancet Oncol. ‒ 2012. ‒ T. 13, № 6. ‒ C. 589-97.
354. Henderson M. A., Burmeister B. H., Ainslie J., Fisher R., Di Iulio J., Smithers B. M., Hong A., Shannon K., Scolyer R. A., Carruthers S., Coventry B. J., Babington S., Duprat J., Hoekstra H. J., Thompson J. F. Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial // Lancet Oncol. ‒ 2015. ‒ T. 16, № 9. ‒ C. 1049-60.